Abstract
Chemically detoxified bacterial toxins are the main or the sole components of several vaccines such as diphtheria, tetanus, pertussis, and cholera. Other toxins are good candidates for novel vaccines, such as the vacuolating cytotoxin of Helicobacter pylori 1. Recently, genetic manipulation of the toxin’s genes has been used to obtain molecules that are already non toxic and do not require chemical treatment for detoxification. This approach has been successful for pertussis2, diphtheria3, cholera and LT toxins4. Preclinical and clinical studies have shown that these molecules have several advantages over the conventional chemically detoxified vaccines. Generally, they are much more immunogenic and induce an immune response, that recognizes better the native toxin molecules. Non toxic derivatives of cholera toxin and LT, in addition to being good candidates for antidiarrheal vaccines, are also mucosal adjuvants5. Therefore, genetically detoxified bacterial toxins not only are good candidates to improve existing vaccines, but they represent new tools for the development of innovative vaccines targeted to the mucosal system.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Marchetti, M., Aricò, B., Burroni, D., Figura, N., Rappuoli, R., and Ghiara, P., 1995, Development of a mouse model of Helicobacter pylori infection that mimics human disease, Science, 267:1655–1658.
Pizza, M., Covacci, A., Bartoloni, A., Perugini, M., Nencioni, L., De Magistris, M.T., Villa, L., Nucci, D., Manetti, R., Bugnoli, M., Giovannoni, F., Olivieri, R., Barbieri, J.T., Sato, H., and Rappuoli, R., 1989, Mutants of pertussis toxin suitable for vaccine development, Science, 246:497–500.
Rappuoli, R., 1990, New and improved vaccines against diphtheria and tetanus. In: Woodrow G.C. and Levine M.M. (eds.). New Generation Vaccines, Marcel Dekker Inc., New York and Basel, pp.251-268.
Pizza, M.G., Fontana, M.R., Giuliani, M.M., Domenighini, M., Magagnoli, C., Giannelli, V., Nucci, D., Hol, W., Manetti, R., and Rappuoli, R., 1994, A genetically detoxified derivative of heat labile E. coli enterotoxin induces neutralizing antibodies against the A subunit, J. Exp. Med., 180:2147–2153.
Douce, G., Turcotte C., Roberts, M., Pizza, M.G., Domenighini, M., Rappuoli, R. and Dougan, G., 1995, Mutants of Escherichia coli heat-labile toxin lacking ADP-ribosyltransferase activity act as non-toxic, mucosal adjuvants. PNAS, 92:1644–1648.
Moxon, R. and Rappuoli, R., 1990, Modern vaccines: Haemophilus influenzae infections and whooping cough, Lancet, i: 1324-1324-1329.
Cherry, J.D., Brunell, P.A., Golden, G.S. and Karzon, D.T., 1988, Report of the task force on pertussis and pertussis immunization-1988, Pediatrics, 81:933–984.
Giammanco, A., Chiarini, A., Straffolini, T., De Mattia, D., Chiaramonte, M., Moschen, M.E. et al. Seroepidemiology of pertussis in Italy, 1991, Rev. Infect. Dis., 13:1216–1220.
Muller, A.S., Leeuwenburg, J. and Pratt, D.S, 1986, Pertussis: epidemiology and control, Bull. WHO, 64:321–331.
Farizo, K.M., Cochi, S.L., Zeii, E.R., Brink, E.W., Wassilak, S.G. and Patriarca, P.A., 1992, Epidemiological features of pertussis in United States, 1980–1989, Clin. Infect. Dis., 14:708–719.
Sutter, R.W., and Cochl, L.M., 1992, Pertussis hospitalization and mortality in the United States, 1985–1988, J. Am. Med. Assoc, 267:386–391.
Sato, Y., Kimura, M. and Fukumi, H., 1984, Development of a pertussis component vaccine in Japan, Lancet, i: 122–126.
Tamura, M., Nogimori, K., Murai, S., Yajima, M., Ito, K., Katada, T., Ui, M., and Ishii, S., 1982, Subunit structure of the islet-activating protein, pertussis toxin, in conformity with the A-B model, Biochemistry, 21:5516 5522.
Nicosia, A., Perugini, M., Franzini, C., Casagli, M.C., Borri, M.G., Antoni, G., Almoni, M., Neri, R, Ratti, G., and Rappuoli, R., 1986, Cloning and sequencing of the pertussis toxin genes: operon structure and gene duplication, PNAS, 83:4631–4635.
Locht, C. and Keith, J., 1986, Pertussis toxin gene: nucleotide sequence and genetic organization, Science, 232:1258–1264.
Nencioni, L., Pizza, M.G., Bugnoli, M., De Magistris, M.T., Di Tommaso, A., Giovannoni, F., Manetti, R., Marsili, I., Matteucci, G., Nucci, D., Olivieri, R., Pileri, P., Presentini, R., Villa, L., Kreeftenberg, H., Silvestri, S., Tagliabue, A., and Rappuoli, R., 1990, Characterization of genetically inactivated pertussis toxin mutants: candidates for a new vaccine against whooping cough, Infect. Immun., 58:1308–1315.
Podda, A., Nencioni, L., De Magistris, M.T., Di Tommaso, A., Bossù, P., Nuti, S., Pileri, P., Peppoloni, S., Bugnoli, M., Ruggiero, P., Marsili, I., D’Errico, A., Tagliabue, A., and Rappuoli, R., 1990, Metabolic, humoral and cellular responses in adult volunteers immunized with the genetically inactivated pertussis toxin mutant PT-9K,129G, J. Exp. Mad., 172:861–868.
Podda, A., Nencioni, L., Marsili, I., Peppoloni, S., Volpini, G., Donati, D., Di Tommaso, A., De Magistris, M.T., and Rappuoli, R., 1991, Phase I clinical trial of an acellular pertussis vaccine composed of genetically detoxified pertussis toxin combined with FHA and 69K, Vaccine, 9:741–745.
Edwards, K.M., 1993, Acellular pertussis vaccines-a solution to the pertussis problem?, J. Infect. Dis., 168:15–20.
Decker, M.D., Edwards, K.M., Steinhoff, M.C., Rennels, M.B., Pichichero, M.E., Englund, J.A., Anderson, E.L., Deloria, M.A., and Reed, G.F., 1995, Comparison of thirteen acellular pertussis vaccines: adverse reactions, Pediatrics, 96(3):557–566.
Edwards, K.M., Meade, B.D., Decker, M.D., Reed, G.F., Rennels, M.B., Steinhoff, M.C., Anderson, E.L., Englung, J.A., Pichichero, M.E., Deloria, M.A., and Deforest, A., 1995, Comparison of thirteen acellular pertussis vaccines: overview and serologic response, Pediatrics, 96(3):548–557.
Munoz, J.J., Peacock, M.G., and Hadlow, W.J., 1987, Anaphylaxis or so-called encephalopathy in mice sensitisized to an antigen with the aid of pertussigen (pertussis toxin), Infect. Immun., 55: 1004–1008.
Kosecka, U., Marshall, J.S., Crowe, S.E., Bienenstock, J., and Perdue, M.H., 1994, Pertussis toxin stimulates hypersensitivity and enhances nerve-mediated antigen uptake in rat intestine, Gastrointest. Liver Physiol, 30:G745–G753.
Anonymous, 1995, Compatibility of acellular pertussis with other vaccines in UK primary immunisation and boosting schedules, PHLS, CAMR, and NIBSC.
Spangler, B.D., 1992, Structure and function of cholera toxin and related Escherichia coli heat-labile enterotoxin, Microbiol. Rev. 56:622–647.
Betley, M.J., Miller, V.L., and Mekalanos, J.J., 1986, Genetics of bacterial enterotoxins, Annu. Rev. Microbiol. 40:577–605.
Rappuoli, R., and Pizza, M., 1991, Structure and evolutionary aspects of ADP-ribosylating toxins. In Sourcebook of Bacterial Protein Toxins, J. Alouf and J. Freer, editors, Academic Press Ltd., London, 1–20.
Del Giudice, G., 1991, Research priorities for diarrhoeal disease vaccines: memorandum from a WHO meeting, Bull WHO, 69:667.
Anonymous, 1994, Cholera-update, end of 1993, Weekly Epidemiological Record, 69(3):13-17.
Fontana, M.R., Manetti, R., Giannelli, V, Magagnoli, C., Marchini, A., Olivieri, R., Domenighini, M., Rappuoli, R., and Pizza, M.G., 1995, Construction of non toxic derivatives of cholera toxin and characterization of the immunological response against the A subunit, Infect. Immun., 63:2356–2360.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1996 Springer Science+Business Media New York
About this chapter
Cite this chapter
Rappuoli, R., Pizza, M., Douce, G., Dougan, G. (1996). New Vaccines Against Bacterial Toxins. In: Cohen, S., Shafferman, A. (eds) Novel Strategies in the Design and Production of Vaccines. Advances in Experimental Medicine and Biology, vol 397. Springer, Boston, MA. https://doi.org/10.1007/978-1-4899-1382-1_8
Download citation
DOI: https://doi.org/10.1007/978-1-4899-1382-1_8
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4899-1384-5
Online ISBN: 978-1-4899-1382-1
eBook Packages: Springer Book Archive